<DOC>
	<DOC>NCT00474266</DOC>
	<brief_summary>The purpose of this study is to demonstrate, in 12-23 month old children, the non-inferiority of the meningococcal vaccine 134612 given with Priorix-Tetra™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children</brief_title>
	<detailed_description>Open multicentre study with 4 treatment groups. Two groups will receive the 134612 vaccine with Priorix-Tetra™ either at the same or different visits followed by a second Priorix-Tetra™ vaccination at 84 days. Two control groups will receive Priorix-Tetra™ and Meningitec™ at different visits followed by a second Priorix-Tetra™ vaccination at 84 days. For all subjects, two blood samples will be taken: prior to and 42 days after the first vaccination. In a subset (30% of subjects in Groups A en C) from selected study centres: additional sample 42 days after second Priorix-Tetra™ dose.</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol. A male or female between, and including, 12 and 23 months of age at the time of the vaccination. Written informed consent obtained from the parent or guardian of the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Previously completed routine childhood vaccinations to the best of parents' or legal guardians' knowledge. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs within six months prior to the vaccine dose. Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before and 42 days after the first dose of vaccine(s). Previous vaccination with meningococcal vaccine of serogroup A, C W and/or Y. History of meningococcal disease. Previous vaccination against measles, mumps, rubella, and/or varicella. History of measles, mumps, rubella and/or varicella. Known exposure to measles, mumps, rubella, varicella or zoster within 30 days prior to vaccination. Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, including neomycin. Major congenital defects or serious chronic illness. Acute disease at the time of enrolment. Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MMRV vaccine</keyword>
	<keyword>co-administration</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>conjugate vaccine</keyword>
</DOC>